This is a single-arm, open-label, multi-center phase II study for subjects with measurable
advanced or recurrent endometrial cancer using pembrolizumab in combination with carboplatin
and paclitaxel chemotherapy. As this combination of agents has not been tested in this
subject population, the first six subjects enrolled will constitute a safety run-in cohort.
Phase:
Phase 2
Details
Lead Sponsor:
Daniela Matei, MD Mario Javier Pineda, MD
Collaborators:
Hoosier Cancer Research Network Merck Sharp & Dohme Corp.